Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
FDA Approves Durvalumab With FLOT for Resectable Gastric and GEJ Cancer
FDA approved durvalumab with FLOT chemotherapy as neoadjuvant and adjuvant treatment for adults with resectable gastric or gastroesophageal junction adenocarcinoma.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved durvalumab, marketed as Imfinzi, with FLOT chemotherapy as neoadjuvant and adjuvant treatment followed by single-agent durvalumab for adults with resectable gastric or gastroesophageal junction adenocarcinoma.
The approval adds immunotherapy to a perioperative treatment pathway that already depends on coordination among medical oncology, surgery and pathology.
For health systems, perioperative approvals often create scheduling, toxicity and sequencing questions that affect the full cancer-care pathway.
Why It Matters
Earlier immunotherapy use in resectable gastrointestinal cancers can shift standards of care before and after surgery.
What to Watch
Watch real-world completion rates, surgical timing and biomarker-informed subgroup analyses.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAGastric CancerDurvalumabPerioperative Oncology